Pyxis Oncology, Inc. announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors. The Company also announced that the second dose level has been initiated in the ongoing Phase 1 trial of PYX-201, a novel antibody-drug conjugate (ADC) product candidate licensed from Pfizer targeting extradomain-B (EDB) of fibronectin, a non-internalizing antigen that is an integral component of the extracellular matrix in tumors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.445 USD | +1.02% | +3.49% | +147.22% |
Mar. 22 | H.C. Wainwright Adjusts Price Target on Pyxis Oncology to $7 From $4, Maintains Buy Rating | MT |
Mar. 21 | Health Care Up on Drug Sales Optimism -- Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+147.78% | 259M | |
-1.39% | 104B | |
+7.08% | 97.47B | |
+5.71% | 22.25B | |
-12.84% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-9.78% | 16.36B | |
+8.59% | 14.39B | |
+38.93% | 12.37B |
- Stock Market
- Equities
- PYXS Stock
- News Pyxis Oncology, Inc.
- Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs